These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 38493955

  • 1. IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.
    Luo J, Chen W, Liu W, Jiang S, Ye Y, Shrimanker R, Hynes G, Klenerman P, Pavord ID, Xue L.
    Mucosal Immunol; 2024 Aug; 17(4):524-536. PubMed ID: 38493955
    [Abstract] [Full Text] [Related]

  • 2. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B, Xue L, Pavord ID.
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [Abstract] [Full Text] [Related]

  • 3. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
    Kelly EA, Esnault S, Liu LY, Evans MD, Johansson MW, Mathur S, Mosher DF, Denlinger LC, Jarjour NN.
    Am J Respir Crit Care Med; 2017 Dec 01; 196(11):1385-1395. PubMed ID: 28862877
    [Abstract] [Full Text] [Related]

  • 4. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
    Hillas G, Fouka E, Papaioannou AI.
    Expert Rev Respir Med; 2020 Apr 01; 14(4):353-365. PubMed ID: 31958239
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mepolizumab for the treatment of severe eosinophilic asthma.
    Poulakos MN, Cargill SM, Waineo MF, Wolford AL.
    Am J Health Syst Pharm; 2017 Jul 01; 74(13):963-969. PubMed ID: 28645995
    [Abstract] [Full Text] [Related]

  • 7. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
    Sehmi R, Smith SG, Kjarsgaard M, Radford K, Boulet LP, Lemiere C, Prazma CM, Ortega H, Martin JG, Nair P.
    Clin Exp Allergy; 2016 Jun 01; 46(6):793-802. PubMed ID: 26685004
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
    Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG.
    Ann Am Thorac Soc; 2014 May 01; 11(4):531-6. PubMed ID: 24606022
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A real-life cohort of mepolizumab treatment in severe eosinophilic asthma.
    Laorden D, Hernández I, Domínguez-Ortega J, Romero D, Álvarez-Sala R, Quirce S.
    Eur Ann Allergy Clin Immunol; 2024 Jul 01; 56(4):169-175. PubMed ID: 36927725
    [Abstract] [Full Text] [Related]

  • 15. Activated sputum eosinophils associated with exacerbations in children on mepolizumab.
    Wilson GE, Knight J, Liu Q, Shelar A, Stewart E, Wang X, Yan X, Sanders J, Visness C, Gill M, Gruchalla R, Liu AH, Kattan M, Khurana Hershey GK, Togias A, Becker PM, Altman MC, Busse WW, Jackson DJ, Montgomery RR, Chupp GL.
    J Allergy Clin Immunol; 2024 Aug 01; 154(2):297-307.e13. PubMed ID: 38485057
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E.
    Adv Ther; 2020 Feb 01; 37(2):718-729. PubMed ID: 31836949
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.
    Smith DA, Minthorn EA, Beerahee M.
    Clin Pharmacokinet; 2011 Apr 01; 50(4):215-27. PubMed ID: 21348536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.